[go: up one dir, main page]

SG11201810525XA - Anti-gitr antibodies and uses thereof - Google Patents

Anti-gitr antibodies and uses thereof

Info

Publication number
SG11201810525XA
SG11201810525XA SG11201810525XA SG11201810525XA SG11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA SG 11201810525X A SG11201810525X A SG 11201810525XA
Authority
SG
Singapore
Prior art keywords
international
new york
saw mill
river road
tarrytown
Prior art date
Application number
SG11201810525XA
Inventor
Frank Delfino
Dimitris Skokos
Bei Wang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201810525XA publication Critical patent/SG11201810525XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 111111111111111111111111111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/214548 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/395 (2006.01) Published: — with international search report (Art. 21(3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US2017/036818 claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) — 09 June 2017 (09.06.2017) with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/348,353 10 June 2016 (10.06.2016) US 62/432,023 09 December 2016 (09.12.2016) US 62/500,312 02 May 2017 (02.05.2017) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). (72) Inventors: DELFINO, Frank; c/o Regeneron Pharmaceu- _ ticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). SKOKOS, Dimitris; c/o Regeneron — Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tar- = rytown, New York 10591 (US). WANG, Bei; c/o Regen- _ eron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). =_ = Agent: CROWLEY-WEBER, Cara, L. et al.; Brownstein = (74) Hyatt Farber Schreck, LLP, 410 Seventeenth Street, Suite 2200, Denver, CO 80202 (US). = = Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = _ = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = MG, MK, MN, MW, MX, MY MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every (84) = — kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = — 1-1 GC 71' EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). In 71' 1-1 ei N (54) Title: ANTI-GITR ANTIBODIES AND USES THEREOF 1-1 0 (57) : Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced ei tumor necrosis factor receptor (GITR) and methods of using the same, including, e.g., methods of treatment using the same.
SG11201810525XA 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof SG11201810525XA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662348353P 2016-06-10 2016-06-10
US201662432023P 2016-12-09 2016-12-09
US201762500312P 2017-05-02 2017-05-02
PCT/US2017/036818 WO2017214548A1 (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11201810525XA true SG11201810525XA (en) 2018-12-28

Family

ID=59078260

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810525XA SG11201810525XA (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof

Country Status (19)

Country Link
US (3) US10738126B2 (en)
EP (2) EP3468999B1 (en)
JP (2) JP7162535B2 (en)
KR (1) KR102495601B1 (en)
CN (1) CN109563170B (en)
AU (1) AU2017278193B9 (en)
BR (1) BR112018075434A2 (en)
CA (1) CA3027121A1 (en)
CL (1) CL2018003515A1 (en)
CO (1) CO2018013298A2 (en)
IL (1) IL263273B2 (en)
MA (1) MA45233A (en)
MX (2) MX2018015350A (en)
MY (1) MY200162A (en)
PH (1) PH12018502502A1 (en)
SG (1) SG11201810525XA (en)
UA (1) UA128687C2 (en)
WO (1) WO2017214548A1 (en)
ZA (1) ZA201807920B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
WO2017214548A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
TWI773694B (en) 2016-10-11 2022-08-11 美商艾吉納斯公司 Anti-lag-3 antibodies and methods of use thereof
FI3552126T3 (en) 2016-12-09 2025-07-08 Regeneron Pharma Systems and methods for sequencing t cell receptors and uses thereof
US10745485B2 (en) * 2018-03-13 2020-08-18 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113412121A (en) 2019-02-12 2021-09-17 瑞泽恩制药公司 Compositions and methods for binding complement and target antigens using bispecific antibodies
RU2734432C1 (en) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds gitr
US20230064703A1 (en) * 2020-01-02 2023-03-02 Nanjing GenScript Biotech Co., Ltd. Anti-gitr antibodies and uses thereof
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
EP4114859A1 (en) * 2020-03-06 2023-01-11 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
CN116761622A (en) * 2021-01-08 2023-09-15 苏州丁孚靶点生物技术有限公司 Pharmaceutical products and their uses
WO2022150654A2 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
WO2022240161A1 (en) * 2021-05-10 2022-11-17 메디맵바이오 주식회사 Anti-gitr antibodies and uses thereof
WO2023175614A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
AU4055697A (en) 1996-08-16 1998-03-06 Schering Corporation Mammalian cell surface antigens; related reagents
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
JP4485049B2 (en) 1997-11-18 2010-06-16 ジェネンテック， インコーポレイテッド Tumor necrosis factor homologue called DNA19355 polypeptide
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
KR20060052681A (en) 2003-05-23 2006-05-19 와이어쓰 Gitr ligand and gitr ligand-related molecules and antibody and uses thereof
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
WO2007084775A2 (en) 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
MX2008014804A (en) 2006-06-02 2009-01-27 Regeneron Pharma High affinity antibodies to human il-6 receptor.
RU2448979C2 (en) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Human antibodies to delta-like human ligand-4
ES2591281T3 (en) 2007-07-12 2016-11-25 Gitr, Inc. Combination therapies that employ GITR binding molecules
JO3182B1 (en) 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
WO2013051718A1 (en) 2011-10-07 2013-04-11 国立大学法人三重大学 Chimeric antigen receptor
KR101549637B1 (en) 2012-06-08 2015-09-03 국립암센터 Novel epitope for switching to Th1 cell and use thereof
AR097306A1 (en) * 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
TW201605896A (en) * 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
SMT202100116T1 (en) 2014-05-28 2021-05-07 Agenus Inc Anti-gitr antibodies and methods of use thereof
PT3151921T (en) 2014-06-06 2019-11-21 Bristol Myers Squibb Co ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEIVER AND USES OF THE SAME
MX2017004311A (en) 2014-10-03 2017-12-07 Dana Farber Cancer Inst Inc Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof.
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
CN107530419B (en) 2014-10-31 2021-05-18 昂考梅德药品有限公司 Combination therapy to treat disease
WO2017214548A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof

Also Published As

Publication number Publication date
EP4344748A2 (en) 2024-04-03
US20210147565A1 (en) 2021-05-20
PH12018502502A1 (en) 2019-04-08
CN109563170A (en) 2019-04-02
IL263273A (en) 2018-12-31
AU2017278193B2 (en) 2024-01-18
AU2017278193B9 (en) 2024-02-01
CL2018003515A1 (en) 2019-03-08
CO2018013298A2 (en) 2019-02-19
US10738126B2 (en) 2020-08-11
EP3468999A1 (en) 2019-04-17
UA128687C2 (en) 2024-10-02
CA3027121A1 (en) 2017-12-14
MA45233A (en) 2019-04-17
MX2018015350A (en) 2019-08-26
US11414494B2 (en) 2022-08-16
AU2017278193A1 (en) 2018-12-13
WO2017214548A1 (en) 2017-12-14
JP2022159476A (en) 2022-10-17
ZA201807920B (en) 2024-01-31
IL263273B2 (en) 2025-10-01
JP2019521098A (en) 2019-07-25
CN109563170B (en) 2023-10-13
MY200162A (en) 2023-12-09
EP3468999B1 (en) 2024-01-10
BR112018075434A2 (en) 2019-03-19
MX2022014695A (en) 2022-12-16
KR20190020297A (en) 2019-02-28
KR102495601B1 (en) 2023-02-06
US20170355774A1 (en) 2017-12-14
EP4344748A3 (en) 2024-06-12
JP7162535B2 (en) 2022-10-28
IL263273B1 (en) 2025-06-01
NZ748619A (en) 2024-05-31
US20230042324A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201909949XA (en) Targeted immunotolerance
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908391XA (en) Methods for modulating an immune response
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201901364VA (en) Engineered target specific nucleases
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201909856XA (en) Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201908790PA (en) Glucocorticoid receptor modulators to treat cervical cancer